Detection of beta-amyloid signature in the lens and its correlation in the brain to aid in the diagnosis of Alzheimer’s disease
Researchers have reported the findings from a clinical trial in which a group of patients clinically diagnosed with probable Alzheimer’s disease ( AD ) were discriminated from an age-matched group of healthy volunteers ( HVs ) with statistical significance ( P
The results from 20 patients with Alzheimer’s disease and 20 healthy volunteers were obtained by a Fluorescent Ligand Eye Scanning ( FLES ) technique that measures a fluorescent signature specific to an exogenous ligand bound to beta-amyloid in the lens of the eye.
Sensitivity and specificity of 85% and 95%, respectively, have been achieved in predicting clinical diagnosis.
Additionally, amyloid brain imaging using Florbetapir F18 positron emission tomography has shown significant correlation with the results obtained in the eye.
The results of the study have demonstrated the safety of the FLES system. ( Xagena )
Kerbage C et al, Am J Alzheimers Dis Other Demen 2014; Epub ahead of print